Evaluation of Plasma Modifications Associated With Rivaroxaban Treatment for Stroke Prevention in Patients With Atrial Fibrillation

Trial Profile

Evaluation of Plasma Modifications Associated With Rivaroxaban Treatment for Stroke Prevention in Patients With Atrial Fibrillation

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms Naco-Nimes
  • Most Recent Events

    • 23 Aug 2016 Status changed from recruiting to completed.
    • 03 Dec 2015 Planned End Date changed from 1 May 2017 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 03 Dec 2015 Planned primary completion date changed from 1 May 2017 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top